Digital therapeutics in Japan: Present and future directions

Area of Science:

• Digital health innovations
• Medical software applications
• Evidence-based interventions

Background:

• Digital therapeutics (DTx) leverage software applications for medical treatment.
• Three DTx apps approved in Japan target nicotine dependence, hypertension, and insomnia.
• These apps offer scalable and accessible healthcare solutions.

Purpose of the Study:

• To review three Japanese-approved Digital Therapeutics (DTx) apps.
• To assess their efficacy in treating nicotine dependence, hypertension, and insomnia.
• To highlight their potential in chronic condition management.

Main Methods:

• Review of clinical trial data for three DTx apps: CureApp SC (nicotine dependence), CureApp HT (hypertension), and SUSMED MedCBT-i (insomnia).
• Analysis of patient outcomes, including abstinence rates, blood pressure reduction, and insomnia scale scores.
• Evaluation of cost-effectiveness and integration into healthcare settings.

Main Results:

• CureApp SC demonstrated significantly higher continuous abstinence rates for nicotine dependence.
• CureApp HT showed significant reductions in systolic blood pressure and potential lifetime cost-effectiveness.
• SUSMED MedCBT-i significantly improved insomnia scores through cognitive behavioral therapy.

Conclusions:

• These DTx apps represent significant advancements in managing chronic conditions.
• They offer scalable, accessible, and evidence-based interventions, addressing challenges in traditional healthcare.
• Further research on long-term efficacy, safety, and cost-effectiveness is crucial for broader integration.